Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director | June 16, 2021 | June 17, 2021 |
| GERON CORPGERN · Entity 4989 | Director · Chairman, President and CEO | February 27, 2025 | March 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date June 16, 2021 · Filed June 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.13 · Expires 2031-06-15 | Direct | 20,000 |
Reported balance
After 2021-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-16 · Grant · Acquired 20,000 · Balance 20,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
GERON CORP
Report date February 27, 2025 · Filed March 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,500 |
Reported balance
After 2025-02-27 transaction · row 1
1 source rowRow 1 · 2025-02-27 · Purchase · Acquired 12,500 · Balance 12,500 F1: The reported transaction represents the open market purchase of 12,500 shares at an executed price of $1.765 per share. |
| Common StockSEC Table I · non-derivative | IndirectJohn A. Scarlett III 1999 Trust | 125,000 |
Reported balance
Holding disclosure · report date 2025-02-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 125,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction represents the open market purchase of 12,500 shares at an executed price of $1.765 per share.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CHIASMA, INC
Report date August 05, 2021 · Filed August 05, 2021
Section 16 reporting ended · disclosed 2021-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-08-05 transaction · row 1
1 source rowRow 1 · 2021-08-05 · Disposition to issuer · Disposed 61,322 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.396 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing five Ordinary Shares of Parent. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.14 | Direct | 0 |
Reported balance
After 2021-08-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-08-05 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F3: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.35 | Direct | 0 |
Reported balance
After 2021-08-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F3: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 | Direct | 0 |
Reported balance
After 2021-08-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F3: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.98 | Direct | 0 |
Reported balance
After 2021-08-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F3: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.81 | Direct | 0 |
Reported balance
After 2021-08-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F3: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time").
F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.396 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing five Ordinary Shares of Parent.
F3: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2025 Filed Mar 3, 2025 11:01 UTC | GERON CORP GERN · Entity 4989 | PurchaseCommon Stock | 12,500 | $1.77 | $22,062.50 |
DisclosureSEC source: 0000950170-25-030329 · ownership.xml · nonDerivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 F1 · kind: The reported transaction represents the open market purchase of 12,500 shares at an executed price of $1.765 per share. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:05 UTC | GERON CORP GERN · Entity 4989 | GrantRestricted Stock Units · Derivative | 410,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-024132 · ownership.xml · derivative · entry 2 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 410,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs were granted on February 18, 2025 and vest in four consecutive equal annual installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. F3 · derivative.expiration_date: The RSUs were granted on February 18, 2025 and vest in four consecutive equal annual installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:05 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 2,457,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0000950170-25-024132 · ownership.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,457,000 Underlying: Common Stock · 2,457,000 shares Expires 2035-02-17 F1 · derivative.exercise_date: This option was granted on February 18, 2025 and vests in 48 consecutive equal monthly installments from the date of grant, provided the Reporting Person continues to provide services to the Issuer through the applicable vesting date. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:10 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0000950170-24-070625 · ownership.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2028-11-06 F1 · derivative.exercise_date: Performance-based stock option granted on November 7, 2018 and vested in full on June 6, 2024 upon approval by the US FDA for imetelstat in lower risk MDS. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0000950170-24-069289 · ownership.xml · derivative · entry 3 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600,000 shares Expires 2026-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction reflects an exercise and sale of options due to expire on February 11, 2026 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on February 20, 2024. F2 · derivative.exercise_date: Option was fully vested. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | SaleCommon Stock | 600,000 | $4.00 | $2,400,000.00 |
DisclosureSEC source: 0000950170-24-069289 · ownership.xml · nonDerivative · entry 2 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 F1 · kind: This transaction reflects an exercise and sale of options due to expire on February 11, 2026 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on February 20, 2024. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionCommon Stock | 600,000 | $2.54 | $1,524,000.00 |
DisclosureSEC source: 0000950170-24-069289 · ownership.xml · nonDerivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction reflects an exercise and sale of options due to expire on February 11, 2026 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on February 20, 2024. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:06 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,000,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001415889-24-004094 · form4-02162024_090200.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director · CHAIRMAN, PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000,000 Underlying: Common Stock · 3,000,000 shares Expires 2034-02-13 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 14, 2024, provided the optionee continues to provide service to the Company. Read SEC document |
| August 15, 2023 Filed Sep 22, 2023 00:32 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (Right to buy) · Derivative | 500,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001062993-23-018393 · form4.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-11-06 F1 · date: Performance-based stock option granted on November 7, 2018 and vested in full on August 15, 2023 upon acceptance of the NDA by the US FDA for imetelstat in lower risk MDS. F1 · derivative.exercise_date: Performance-based stock option granted on November 7, 2018 and vested in full on August 15, 2023 upon acceptance of the NDA by the US FDA for imetelstat in lower risk MDS. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 00:16 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (Right to buy) · Derivative | 1,750,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001062993-23-004898 · form4.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750,000 Underlying: Common Stock · 1,750,000 shares Expires 2033-02-21 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 22, 2023, provided the optionee continues to provide service to the Company. Read SEC document |
| February 10, 2023 Filed Feb 11, 2023 02:47 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 446,668 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001062993-23-002790 · form4.xml · derivative · entry 9 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 446,668 shares Expires 2023-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. F1 · derivative.exercise_date: Option was fully vested. Read SEC document |
| February 10, 2023 Filed Feb 11, 2023 02:47 UTC | GERON CORP GERN · Entity 4989 | SaleCommon Stock | 446,668 | $3.00 | $1,340,004.00 |
DisclosureSEC source: 0001062993-23-002790 · form4.xml · nonDerivative · entry 6 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. Read SEC document |
| February 10, 2023 Filed Feb 11, 2023 02:47 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionCommon Stock | 446,668 | $1.50 | $670,002.00 |
DisclosureSEC source: 0001062993-23-002790 · form4.xml · nonDerivative · entry 5 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. Read SEC document |
| February 09, 2023 Filed Feb 11, 2023 02:47 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 446,666 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001062993-23-002790 · form4.xml · derivative · entry 8 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 446,666 shares Expires 2023-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. F1 · derivative.exercise_date: Option was fully vested. Read SEC document |
| February 09, 2023 Filed Feb 11, 2023 02:47 UTC | GERON CORP GERN · Entity 4989 | SaleCommon Stock | 446,666 | $3.03 | $1,353,397.98 |
DisclosureSEC source: 0001062993-23-002790 · form4.xml · nonDerivative · entry 4 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. Read SEC document |
| February 09, 2023 Filed Feb 11, 2023 02:47 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionCommon Stock | 446,666 | $1.50 | $669,999.00 |
DisclosureSEC source: 0001062993-23-002790 · form4.xml · nonDerivative · entry 3 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 02:47 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 446,666 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001062993-23-002790 · form4.xml · derivative · entry 7 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 446,666 shares Expires 2023-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. F1 · derivative.exercise_date: Option was fully vested. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 02:47 UTC | GERON CORP GERN · Entity 4989 | SaleCommon Stock | 446,666 | $3.08 | $1,375,731.28 |
DisclosureSEC source: 0001062993-23-002790 · form4.xml · nonDerivative · entry 2 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 02:47 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionCommon Stock | 446,666 | $1.50 | $669,999.00 |
DisclosureSEC source: 0001062993-23-002790 · form4.xml · nonDerivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 23:03 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (Right to buy) · Derivative | 2,100,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001062993-22-005003 · form4.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100,000 Underlying: Common Stock · 2,100,000 shares Expires 2032-02-15 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 16, 2022, provided the optionee continues to provide service to the Company. Read SEC document |
| August 05, 2021 Filed Aug 5, 2021 17:57 UTC | CHIASMA, INC CHMA · Entity 136487 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $5.81 | $0.00 |
DisclosureSEC source: 0001209191-21-050037 · doc4.xml · derivative · entry 6 SCARLETT JOHN A · CIK 0001270928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F3 · kind: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F3 · derivative.expiration_date: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. Read SEC document |
| August 05, 2021 Filed Aug 5, 2021 17:57 UTC | CHIASMA, INC CHMA · Entity 136487 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $7.98 | $0.00 |
DisclosureSEC source: 0001209191-21-050037 · doc4.xml · derivative · entry 5 SCARLETT JOHN A · CIK 0001270928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F3 · kind: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F3 · derivative.expiration_date: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. Read SEC document |
| August 05, 2021 Filed Aug 5, 2021 17:57 UTC | CHIASMA, INC CHMA · Entity 136487 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001209191-21-050037 · doc4.xml · derivative · entry 4 SCARLETT JOHN A · CIK 0001270928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F3 · kind: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F3 · derivative.expiration_date: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. Read SEC document |
| August 05, 2021 Filed Aug 5, 2021 17:57 UTC | CHIASMA, INC CHMA · Entity 136487 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-21-050037 · doc4.xml · derivative · entry 3 SCARLETT JOHN A · CIK 0001270928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F3 · kind: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F3 · derivative.expiration_date: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. Read SEC document |
| August 05, 2021 Filed Aug 5, 2021 17:57 UTC | CHIASMA, INC CHMA · Entity 136487 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0001209191-21-050037 · doc4.xml · derivative · entry 2 SCARLETT JOHN A · CIK 0001270928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F3 · kind: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F3 · derivative.expiration_date: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. Read SEC document |
| August 05, 2021 Filed Aug 5, 2021 17:57 UTC | CHIASMA, INC CHMA · Entity 136487 | Disposition to issuerCommon Stock | 61,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-050037 · doc4.xml · nonDerivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2 · price: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.396 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing five Ordinary Shares of Parent. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 18:46 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0001567619-21-012369 · doc1.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| February 02, 2021 Filed Feb 5, 2021 00:44 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (Right to buy) · Derivative | 600,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0000886744-21-000015 · edgar.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2031-02-01 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 2, 2021, provided the optionee continues to provide service to the Company. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 15:01 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001567619-20-012361 · doc1.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:27 UTC | CHIASMA, INC CHMA · Entity 136487 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $5.81 | $0.00 |
DisclosureSEC source: 0001209191-20-036471 · doc4.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: The shares of Common Stock underlying the option will vest upon the earlier of (i) June 11, 2021 or the (ii) the date of the issuer's next annual meeting of the stockholders. Read SEC document |
| February 12, 2020 Filed Feb 15, 2020 00:38 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 582,750 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0000886744-20-000026 · edgar.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 582,750 Underlying: Common Stock · 582,750 shares Expires 2030-02-11 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 12, 2020 provided the optionee continues to provide services to the Company. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 14:06 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $11.31 | $0.00 |
DisclosureSEC source: 0001567619-19-013827 · doc1.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 18:53 UTC | CHIASMA, INC CHMA · Entity 136487 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $7.98 | $0.00 |
DisclosureSEC source: 0001209191-19-037505 · doc4.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-13 F1 · derivative.exercise_date: The shares of Common Stock underlying the option will vest upon the earlier of (1) June 13, 2020 and (ii) the date of the issuer's next annual meeting of the stockholders. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 23:58 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 1,050,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000886744-19-000022 · edgar.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050,000 Underlying: Common Stock · 1,050,000 shares Expires 2029-01-29 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing January 30, 2019 provided the optionee continues to provide services to the Company. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 17:47 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0000899243-18-016814 · doc4.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2028-06-12 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 16:22 UTC | CHIASMA, INC CHMA · Entity 136487 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001209191-18-036944 · doc4.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2028-06-07 F1 · security: Stock Option granted in accordance with the Issuer's Non-Employee Director Compensation Policy. F2 · derivative.exercise_date: The shares of Common Stock underlying the option will vest upon the earlier of (1) June 7, 2019 and (ii) the date of the Issuer's 2019 annual meeting of the stockholders. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 23:10 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 1,050,000 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0000886744-18-000018 · edgar.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050,000 Underlying: Common Stock · 1,050,000 shares Expires 2028-01-31 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing January 31, 2018 provided the optionee continues to provide services to the Company. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 13:57 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $13.78 | $0.00 |
DisclosureSEC source: 0001140361-17-025788 · doc1.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: The option vests in full on June 20, 2018 subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 16:04 UTC | CHIASMA, INC CHMA · Entity 136487 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-17-040782 · doc4.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2027-06-15 F1 · security: Stock Option granted in accordance with the Issuer's Non-Employee Director Compensation Policy. F2 · derivative.exercise_date: The shares of Common Stock underlying the option will vest upon the earlier of (1) June 15, 2018 and (ii) the date of the Issuer's 2018 annual meeting of the stockholders. Read SEC document |
| February 09, 2017 Filed Feb 11, 2017 01:15 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 1,050,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0000886744-17-000012 · edgar.xml · derivative · entry 1 SCARLETT JOHN A · CIK 0001270928 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050,000 Underlying: Common Stock · 1,050,000 shares Expires 2027-02-09 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 9, 2017 provided the optionee continues to provide services to the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.